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Abstract. 
 
Occludin, the putative tight junction integral 
membrane protein, is an attractive candidate for a pro-
tein that forms the actual sealing element of the tight 
junction. To study the role of occludin in the formation 
of the tight junction seal, synthetic peptides (OCC1 and 
OCC2) corresponding to the two putative extracellular 
domains of occludin were assayed for their ability to al-
ter tight junctions in 
 
Xenopus
 
 kidney epithelial cell line 
A6. Transepithelial electrical resistance and paracellu-
lar tracer flux measurements indicated that the second 
extracellular domain peptide (OCC2) reversibly dis-
rupted the transepithelial permeability barrier at con-
centrations of 
 
,
 
 5 
 
m
 
M. Despite the increased paracellu-
lar permeability, there were no changes in gross 
epithelial cell morphology as determined by scanning 
EM. The OCC2 peptide decreased the amount of oc-
cludin present at the tight junction, as assessed by indi-
rect immunofluorescence, as well as decreased total cel-
lular content of occludin, as assessed by Western blot 
analysis. Pulse-labeling and metabolic chase analysis 
suggested that this decrease in occludin level could be 
attributed to an increase in turnover of cellular occlu-
din rather than a decrease in occludin synthesis. The ef-
fect on occludin was specific because other tight junc-
tion components, ZO-1, ZO-2, cingulin, and the adher-
ens junction protein E-cadherin, were unaltered by 
OCC2 treatment. Therefore, the peptide corresponding 
to the second extracellular domain of occludin perturbs 
the tight junction permeability barrier in a very specific 
manner. The correlation between a decrease in occlu-
din levels and the perturbation of the tight junction per-
meability barrier provides evidence for a role of occlu-
din in the formation of the tight junction seal.
 
T
 
he
 
 tight junction, also known as 
 
zonula occludens
 
,
is the apical-most component of the junctional com-
plex of epithelial and endothelial cells. It is a region
where the plasma membrane of adjacent cells forms a se-
ries of contacts that appears to completely occlude the ex-
tracellular space as observed by transmission EM. These
contact points of the tight junction correspond to a net-
work of intramembrane fibrils, when studied by freeze-
fracture EM, which completely circumscribes the apices of
cells (9).
Two main functions have been attributed to the tight
junction. First, the tight junction seals the intercellular
space and is responsible for the separation of apical and
basolateral fluid compartments of epithelia and endothe-
lia. Macromolecules of radii 
 
> 
 
15 Å cannot flow through the
tight junction (23). However, depending on the properties
of each individual epithelium, small ions can pass through
the tight junction to varying degrees, as indicated by dif-
ferences in transepithelial electrical resistance in various
epithelial and endothelial cells (5 
 
V
 
 cm
 
2
 
 to 
 
.
 
 5,000 
 
V
 
 cm
 
2
 
)
(13, 29). Therefore, the tight junction is crucial for the for-
mation of blood–tissue barriers, such as the blood–brain
barrier and the blood–retinal barrier, which are absolutely
essential for the normal functioning of the organism (30,
34). Second, the tight junction functions as a diffusion bar-
rier to plasma membrane lipids and proteins, which helps
to define apical and basolateral membrane domains of
these polarized epithelial and endothelial cells (18, 20).
Therefore, the tight junction is crucial for the epithelium
to generate chemical and electrical gradients across the
cell monolayer that is necessary for vectorial transport
processes such as absorption and secretion.
The tight junction is regulated in response to various
physiological and tissue-specific needs. For example, the
tight junction permeability to nutrients has been shown to
be increased by intestinal luminal glucose after food in-
take, suggesting that the regulation of tight junction per-
meability has a role in absorption of nutrients in the intes-
tine (4, 6). A number of hormones have been shown to
affect the tight junction, including transforming growth
factors (
 
a
 
 and 
 
b
 
) (8, 35) and glucocorticoids (37). Disrup-
tion of the tight junction has been found to occur in many
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diseases including hepatitis, Celiac Spruce, Crohn’s dis-
ease, and gastritis, in which the tight junction intramem-
brane fibrils of the respective epithelia manifest discontin-
ues and poor organizations (21, 24, 28, 33). On the other
hand, increases in tight junctional depth in intestinal epi-
thelium in Blind Loop syndrome correlate with a decrease
in permeability to nutrients (31). In addition, the tight
junction is regulated in various physiological processes,
such as leukocyte transmigration across an endothelium
(26) and intestinal cell division (5) and extrusion (7), to en-
sure minimal disruption of the tight junction barrier.
Therefore, the tight junction appears to function as more
than just a paracellular seal, and instead is regulated in
physiologically important processes.
While the physiological significance of the tight junction
is well recognized, the molecular component(s) involved
in the formation of a functional tight junction barrier are
not yet established. Several cytoplasmic peripheral mem-
brane proteins (ZO-1, ZO2, cingulin, 7H6, and rab 13) (1,
2, 11, 12, 20, 32, 36, 38, 39) and one integral membrane
protein (occludin) (15) have been found to localize at the
tight junction. Occludin was shown to localize to junc-
tional fibrils by immunogold labeling of freeze-fracture
replicas of tight junctions (14). The cytoplasmic tail of oc-
cludin is necessary for its localization to cell–cell contacts,
perhaps via binding to ZO-1 and ZO-2 (16). However,
how these proteins function in the formation of the tight
junction permeability barrier is unclear.
Occludin, being the only putative integral membrane
protein so far identified, is a candidate for the formation of
the functional intercellular seal of the tight junction. The
primary amino acid sequence of chick occludin predicts
four membrane-spanning regions and two 44–amino acid
extracellular loops. Both extracellular domains of occludin
consist solely of uncharged residues with the exception of
one or two charged residues adjacent to the transmem-
brane regions (3). The nonpolar nature of the extracellular
domains and the conservation of their sequences between
five species (human, mouse, dog, chick, and rat–kangaroo)
suggest that the extracellular domains have important func-
tional roles, perhaps in the formation of the actual contact
seal of the tight junction. To test this hypothesis, we made
synthetic peptides corresponding to each of the putative
extracellular domains of chick occludin and assayed for
their ability to alter tight junction barrier function.
 
Materials and Methods
 
Cell Culture, Calcium Switch Assay, and Measurement 
of Transepithelial Resistance
 
The A6.2 subclone of the 
 
Xenopus
 
 kidney epithelial A6 cell line (27) was
grown on Transwell filters (Costar Corp., Cambridge, MA) in 89% DME
(1 g/liter glucose) supplemented with 0.74 g/liter bicarbonate, 5.95 g/liter
Hepes (pH 7.4), and 5% FCS and maintained at 28
 
8
 
C and 1% CO
 
2
 
. For
the calcium switch assay (17, 19, 25), A6 cells were allowed to grow in nor-
mal growth medium to confluency and were subsequently changed to low
calcium medium for 18 h. At the end of the low calcium (
 
,
 
 50 
 
m
 
M) incu-
bation, A6 cells were replenished with normal calcium media, and the for-
mation of tight junctions was monitored by the generation of transepithe-
lial electrical resistance (TER).
 
1
 
 TER was measured directly in normal
growth media in Transwell wells. A short 4-
 
m
 
A current pulse was passed
across the cell monolayer using a pair of calomel electrodes via KCl salt
bridges, and the voltage was measured by a conventional voltmeter across
the same cell monolayer using a pair of Ag/AgCl electrodes via KCl salt
bridges. TER was calculated from the measured voltage and normalized
by the area of the monolayer. The background TER of blank Transwell
filters was subtracted from the TER of cell monolayers.
 
Peptide Synthesis and Treatment of Cells
 
Peptides OCC1 corresponding to amino acids 81–125 of chick occludin (44
amino acids [aa] 
 
5
 
 DYGYGLGGAYGTGLGGFYGSNYYGSGLSYS-
YGYGGYYGGVNQRT) and OCC2 corresponding to amino acids 184–
227 of chick occludin (44 aa 
 
5
 
 GVNPQAQMSSGYYYSPLLAMC-
SQAYGSTYLNQYIYHYCTVDPQE) are the entire first and second pu-
tative extracellular domains of chick occludin, respectively. Two different
peptide forms of the second extracellular domain were synthesized. The
first peptide, OCC2, was modified at the two cysteine residues of the ex-
tracellular domain by covalent linkage to acetamidomethyl (
 
underlined
 
)
to prevent formation of disulfide bond(s). An unmodified form of the sec-
ond extracellular domain peptide without the protection groups at the two
cysteine residues, OCC2(U), was also synthesized. A scrambled peptide
OCC2(S) composed of a scrambled sequence of the same residues as
OCC2, including the acetamidomethyl modification at cysteines, was also
synthesized (44 aa 
 
5
 
 GACQVYDPYMSGNYPAQSLMYQNLQYLVS-
GIHTYPECSYATQSY). Peptides were prepared as 10 mM stock solu-
tions in DMSO and were added to both sides of the Transwell bathing
wells. All peptides were synthesized by the Microchemistry Core Facility
at the Memorial Sloan-Kettering Cancer Center (New York).
 
Paracellular Tracers Flux Assay
 
Flux assays were performed on 6.5-mm Transwell (in 24-well cell culture
dishes). Four different paracellular tracers, [
 
3
 
H]mannitol (Amersham
Corp., Arlington Heights, IL), [
 
14
 
C]inulin (Amersham Corp.), neutral
dextran (mol wt 3,000) conjugated with Texas red (Molecular Probes, Eu-
gene, OR), and neutral dextran (mol wt 40,000) conjugated with Texas
red (Molecular Probes), were used. At the beginning of the flux assay,
both sides of the bathing wells of Transwell filters were replaced with
fresh media without peptides (containing 5 mM unlabeled mannitol [mol
wt 184] and 1 mM unlabeled inulin [mol wt 5,200]). Each tracer was added
to a final concentration of 3.6 nmol for [
 
3
 
H]mannitol, 0.36 nmol for
[
 
14
 
C]inulin, 25 
 
m
 
g/100 
 
m
 
l for dextran (mol wt 3,000), or 50 
 
m
 
g/100 
 
m
 
l for
dextran (mol wt 40,000) to the apical bathing wells that contained 100 
 
m
 
l
of media. The basal bathing well had no added tracers and contained 700 
 
m
 
l
of the same flux assay media as in the apical compartment. All flux assays
were performed at 25
 
8
 
C with gentle circular agitation. Cell monolayers
were first allowed to equilibrate for 30 min after the addition of tracers.
At each of the following 15-min time intervals, the entire Transwell filter
cup was removed from the basal bathing well and transferred to a fresh
basal bathing well containing 700 
 
m
 
l of the flux assay media. Three 15-min
flux sampling intervals were taken, and the mean was used for the calcula-
tion of paracellular tracer flux that is taken as [amount of tracer in the
basal bathing media]/[time]. For [
 
3
 
H]mannitol and [
 
14
 
C]inulin flux, the en-
tire 700 
 
m
 
l of the basal media was added to 5 ml of scintillation fluid, and
 
3
 
H and 
 
14
 
C were counted. The concentration of [
 
3
 
H]mannitol and [
 
14
 
C]in-
ulin in the basal bathing media was calculated from a titration curve of
known concentration of the same tracers. For dextran (3 kD and 40 kD),
the concentration was calculated from the amount of fluorescence emis-
sion at 610 nm (excitation at 587 nm) using a titration curve of known con-
centration of the same tracers.
 
Immunofluorescence Staining and Western Blotting
 
A6 cells were grown on Transwell filters and TER was measured before
and after peptide treatment. For immunofluorescence, cells were fixed
with 100% methanol at 
 
2
 
20
 
8
 
C for 30 min and dried with 100% acetone at
 
2
 
20
 
8
 
C for 5 min. Filters were blocked with immunofluorescence staining
buffer (1% nonfat dry milk in 0.5% Triton X-100, 5 mM EDTA, 0.15 M
NaCl, and 20 mM Hepes, pH 7.0) before incubation with primary antibod-
ies. Rabbit anti–occludin antibodies were raised against a glutathione-
 
S
 
-transferase fusion protein of the cytoplasmic domain of chick occludin
(255–510 aa). Rabbit anti–ZO-1 (No. 10153) and –ZO-2 (No. 9989) (22)
antibodies were gifts from D. Goodenough (Harvard Medical School,
Cambridge, MA). Rabbit anti–cingulin antibodies were gifts from S. Citi
(University of Padua, Italy). Monoclonal mouse anti–
 
Xenopus
 
 E-cadherin
 
1.
 
 Abbreviations used in this paper
 
: aa, amino acid; TER, transepithelial
electrical resistance. 
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antibodies (5D3) were raised against the extracellular domain of E-cad-
herin (10). FITC-conjugated secondary antibodies were obtained from
Molecular Probes. For Western blot analysis, cells were rinsed twice in
PBS and extracted directly in SDS-PAGE sample buffer (50 mM Tris-
HPO
 
4
 
, pH 6.8, 2.5 mM EDTA, 15% sucrose, 2% SDS, and 50 mM DTT)
containing protease inhibitors (5 mM PMSF, 5 
 
m
 
g/ml pepstatin A, 1 
 
m
 
g/ml
 
N
 
-
 
a
 
-
 
p
 
-tosyl-
 
l
 
-lysine-chloromethyl ketone (TLCK), 10 
 
m
 
g/ml leupeptin, 20
 
m
 
g/ml aprotinin, 50 
 
m
 
g/ml antipain, 2 mM benzamidine, 50 
 
m
 
g/ml soybean
trypsin inhibitor, and 2.5 mM iodoactamide). Samples were boiled for 10
min, and cooled to room temperature before the addition of iodoacetic
acid to a final concentration of 125 mM, and then SDS-PAGE was per-
formed. Western blots for occludin, ZO-1, ZO-2, cingulin, and E-cad-
herin were done using the same primary antibodies as those for immuno-
fluorescence stainings. Secondary antibodies conjugated with HRP (Bio
Rad Laboratories, Hercules, CA) were developed by enhanced chemilu-
minescence (Amersham Corp.).
 
Metabolic Labeling, Immunoprecipitations,
and Fluorography
 
A6 cells were grown on 75-mm Transwell filters. To examine the turnover
of occludin, each monolayer was labeled with 0.8 mCi [
 
35
 
S]methionine in
methionine-free media (supplemented with 5% FBS) for 22 h, and protein
turnover was monitored by replacing labeling media with fresh media in
the presence or absence of 10 mM OCC2 for 12 h. Cells were extracted for
immunoprecipitation either immediately at the end of the labeling period
(
 
t
 
 
 
5
 
 0) or at 12 h after the end of the labeling period (
 
t
 
 
 
5
 
 12 h). For exam-
ination of occludin synthesis, cells were rinsed once with methionine-free
media and incubated in methionine-free media for 30 min before meta-
bolic labeling. Each Transwell cell monolayer was then briefly labeled for
2 h with 1.5 mCi [
 
35
 
S]methionine in methionine-free media (supplemented
with 5% dialyzed FBS) in the presence or absence of 5 
 
m
 
M OCC2 before
extraction for immunoprecipitation. Pulse-labeling experiments were also
performed on cells pretreated with 5 
 
m
 
M OCC2 for 20 h. For immunopre-
cipitation, cells from each 75-mm Transwell cell monolayer were extracted
with 2 ml 1% SDS containing 5 mM EDTA and protease inhibitors (5 mM
PMSF, 5 
 
m
 
g/ml pepstatin A, 1 
 
m
 
g/ml TLCK, 10 
 
m
 
g/ml leupeptin, 20 
 
m
 
g/ml
aprotinin, 50 
 
m
 
g/ml antipain, 2 mM benzamidine, 50 
 
m
 
g/ml soybean tryp-
sin inhibitor, and 2.5 mM iodoactamide). Each sample was boiled for 10
min before the addition of Triton X-100, deoxycholate, NaCl, and Hepes
to a final concentration of 0.2% SDS, 1% Triton X-100, 0.5% deoxycho-
late, 0.15 M NaCl, and 20 mM Hepes (pH 7.4). Immunoprecipitation was
performed with protein A–Sepharose (Sigma Chemical Co., St. Louis,
MO) in the presence of rabbit anti–chick occludin antibodies (see above)
or preimmune serum. Immunoprecipitates were prepared for SDS-PAGE
as described above. Polyacrylamide gels were fixed with 50% methanol
and 10% acetic acid for 1 h and incubated in Amplify (Amersham Corp.)
for 45 min before being dried under vacuum. Dried gels were exposed to
Hyperfilm-MP (Amersham Corp.) at 
 
2
 
80
 
8
 
C.
 
Scanning EM
 
A6 cells were plated on Thermanox coverslips (Nunc, Inc., Napaville,
IL) coated with polylysine and were allowed to grow to confluency. Cells
were either untreated or treated for 40 h with 10 
 
m
 
M OCC1 or 10 
 
m
 
M
OCC2. Subsequently, the cells were rinsed twice in PBS and fixed with
2.5% glutaraldehyde/20 mM Pipes/pH 7.5 at room temperature over-
night. Coverslips were rinsed in 20 mM Pipes/pH 7.5, followed by dehy-
dration in a graded series of alcohol (50%, 75%, 95%, through absolute
alcohol) and critical point dried in a DCP-1 critical point dryer (Denton
Vacuum Inc., Cherry Hill, NJ). The samples were sputter coated with
gold/palladium in a Hummer VI sputtering system (Technic Inc., Provi-
dence, RI). The samples were photographed using a JSM 35 scanning
electron microscope (JEOL USA, Peabody, MA). All EM was performed
by Nina Lampen in the Electron Microscopy Facility at the Memorial
Sloan-Kettering Cancer Center.
 
Results
 
Expression and Localization of Occludin
in A6 Cells Correlate with the Development of 
Transepithelial Resistance
 
The 
 
Xenopus
 
 kidney epithelial A6 cell line formed mono-
Figure 1. Expression and junctional localization of occludin cor-
related with the development of tight junctions in Xenopus A6
kidney epithelial cells. A6 cells were allowed to grow to confluency
in Transwell filters in normal medium and were subsequently
changed to low calcium medium for 18 h. Then the medium was
replenished with normal calcium (t 5 0), and the formation of tight
junctions was monitored by measuring TER at t 5 0 h (TER 5
Vcm2), t 5 15 h (TER z0 Vcm2), t 5 3 d (TER z100 Vcm2),
and t 5 5 d (TER . 1,000 Vcm2). (a) Indirect immunofluores-
cence of occludin in A6.2 cells at t 5 0, 15 h, 3 d, and 5 d. (b)
Western blots of A6 cell lysate for occludin, cingulin, and ZO-1 at t
5 0, 15 h, 3 d, and 5 d. 
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layers that had a very high TER of 
 
z
 
8,000 
 
V
 
cm
 
2
 
 and were
impermeable to macromolecules of mol wt 
 
> 
 
40 kD. After
induction of synchronized intercellular junction formation
by a calcium switch assay (see Materials and Methods for
details), occludin localization at cell boundaries correlated
with the formation of tight junctions as monitored by mea-
surements of TER (Fig. 1 
 
a
 
). Western blot analysis of A6
total cell lysates using polyclonal antibodies raised against
the cytoplasmic domain of chick occludin showed a single
band of mol wt z60 kD corresponding to Xenopus occlu-
din. A minor band of lower molecular weight is detected
only occasionally, and therefore is presumed to be a degra-
dation product of occludin. The expression levels of occlu-
din during tight junction formation correlated roughly
with the increase in TER (Fig. 1 b). The increase in occlu-
din expression plateaued as TER reached maximal steady-
state levels (not shown). By Western blot analysis, ZO-1
and cingulin levels also increased during tight junction de-
velopment (Fig. 1 b), but their expression levels changed
less dramatically and tended to plateau earlier than the
TER or occludin levels. The time course of occludin local-
ization and expression was consistent with the hypothesis
that occludin participates in the formation of the tight
junction.
TER Is Reduced by a Synthetic Peptide (OCC2) 
Corresponding to the Second Extracellular Domain
of Occludin
The predicted topology of occludin from the chick occludin
amino acid sequence consists of two short extracellular do-
mains, each one having 44 residues. Synthetic peptides
corresponding to either the entire first or second extracel-
lular domain were made and assayed for their ability to af-
fect tight junctions as assessed by measurements of TER.
Treatment of A6 cell monolayers with the second extracel-
lular domain peptide (OCC2) caused a substantial reduc-
tion of TER from z6,000 Vcm2 to z900 Vcm2 (Fig. 2 a). In
contrast, the first extracellular domain peptide (OCC1) did
not alter TER as compared with the DMSO only control
(Fig. 2 a). Additionally, a control peptide containing a
scrambled amino acid sequence from the second extracel-
lular domain, OCC2(S), had no effect on TER (Fig. 2 a).
Therefore, the peptide corresponding to the second extra-
cellular domain of chick occludin (OCC2) specifically re-
duced TER in Xenopus kidney epithelial A6 cell monolayers.
OCC2 was synthesized with a protection group, aceta-
midomethyl, covalently linked to the sulfhydryls of the
two cysteine residues of the peptide. When the peptide
was synthesized without the protection groups, OCC2(U)
(U stands for unmodified), no change in TER was ob-
served at concentrations that worked maximally for the
protected peptide OCC2 (data not shown). The addition
of acetamidomethyl protection groups to the two cysteine
residues increased the hydrophilicity of OCC2 (as judged
by a mobility shift using HPLC; data not shown) and pre-
final concentration of 0.5, 1, 2, 5, and 10 mM OCC2. TER was
measured at 40 h after peptide addition. The TER of each indi-
vidual monolayer is plotted. Each concentration of OCC2 was
done on duplicate monolayers. All error bars represent standard
error.
Figure 2. A synthetic peptide (OCC2) corresponding to the en-
tire second extracellular domain of chick occludin decreased
TER of A6 cell monolayers. (a) Effect of various synthetic pep-
tides on TER. OCC1 (corresponding to the entire first extracellu-
lar domain of chick occludin), OCC2 (corresponding to the entire
second extracellular domain of chick occludin), OCC2(S) (corre-
sponding to the scrambled sequence of the entire second extra-
cellular domain of chick occludin), and DMSO solvent control
were used. Newly confluent A6 cell monolayers (starting TER
z1,000 Vcm2) that were still developing TER were used. Cell
monolayers were treated with a final concentration of 5 mM
OCC1, 5 mM OCC2, 5 mM OCC2(S), or DMSO (0.05%) for 66 h,
and peptides were replenished every 24 h. At the end of the
66-h peptide incubation, TER for control monolayers reached
z5,000–6,000 Vcm2. n 5 6 for each condition. (b) Time course of
effect of OCC2 peptide on TER of A6 cells that were still devel-
oping TER. Cell monolayers that had attained TER z750 Vcm2
were treated with a final concentration of 5 mM OCC1 (n 5 4) or
5 mM OCC2 (n 5 5) at t 5 0. Peptides were replenished at 30 h.
(c) Dose dependency of OCC2 peptide on TER in A6 cell mono-
layers that were still developing TER. A6.2 cells were allowed to
grow to confluency in normal medium and were subsequently
changed to low calcium medium for 18 h. The low calcium me-
dium was replaced with normal calcium medium containing a fi-
nal concentration of 0.2, 0.5, 2, and 5 mM OCC2. TER were mea-
sured after 4 d when control cell monolayers developed TER of
z3,000 Vcm2. n 5 3 for all concentrates tested. (d) Time course
of OCC2 peptide on TER of steady-state A6 cell monolayers that
were confluent for z2 wk (TER z8,000 Vcm2). Cells were
treated with a final concentration of 5 mM OCC2 at t 5 0. Un-
treated monolayers were done in parallel as control. Peptides
were replenished at 22 and 76 h. n 5 3 for all conditions. (e) Dose
dependency of OCC2 peptide on TER in steady-state A6 mono-
layers (TER z6,000 Vcm2). Cell monolayers were treated with aWong and Gumbiner Occludin in Tight Junctions 403
vented intermolecular disulfide bond formation (as judged
by formation of a ladder of higher molecular weight forms
using SDS-PAGE; data not shown). Either effect may
contribute to the enhanced effectiveness of the protected
peptide.
The magnitude of change in TER by treatment with
OCC2 depended on the growth state of the cells and the
dosage used. The time course and dose response of the
OCC2-induced decrease in TER were assayed on both
newly formed monolayers that were developing TER
(TER  z1,000  Vcm2) and steady-state monolayers that had
completely formed maximal TER (TER z8,000–10,000
Vcm2). Newly formed monolayers were studied either by
plating A6 cells at confluent density or by inducing junc-
tion formation with the low calcium switch assay (see Ma-
terials and Methods); both procedures yielded the same
results. For newly formed monolayers that were still devel-
oping TER (see figure legends for details), OCC2 treat-
ment resulted in a z10-fold lower TER of z250 Vcm2 as
compared with z2,500 Vcm2 in 2 d (Figure 2 b). Treat-
ment with the first extracellular domain peptide, OCC1,
had no effect (Fig. 2 b). The ability of OCC2 to decrease
TER in newly formed monolayers was dose dependent
with a maximal inhibition at the final concentration of 5 mM
OCC2, resulting in a z10-fold lower TER of z400 Vcm2
as compared with z3,500 Vcm2 (Fig. 2 c). For steady-state
monolayers that had been confluent for .10 d and at-
tained a maximal TER (z10,000 Vcm2), OCC2 decreased
TER from z10,000 Vcm2 to z2,000 Vcm2, whereas un-
treated monolayers retained a stable maximal TER (Fig.
2 d). However, the effect of OCC2 on steady-state mono-
layers took much longer than it did for newly formed
monolayers. It took 5 d to attain an approximately fivefold
decrease in TER in steady-state monolayers as compared
with 2 d for newly formed monolayers. The effect of
OCC2 on steady-state monolayers was also dose depen-
dent with a maximal inhibition at 5 mM when TER de-
creased from z6,000 Vcm2 to z800 Vcm2 (Fig. 2 e). This
agreed well with the dose required for newly formed
monolayers, suggesting that OCC2 peptide acted in similar
manner in both growth states. (It is important to point out
that the OCC2 peptide is somewhat water insoluble, and
therefore its actual effective concentration in solution is
unclear.) In conclusion, the second extracellular domain
peptide of chick occludin (OCC2) decreased the TER of
Xenopus A6 cell monolayers in a time- and dose-depen-
dent manner, and the magnitude and time course of the ef-
fect depended on the growth state of the cells. Additional
experiments carried out using the calcium switch method,
in which peptides were added before TER development,
showed that OCC2 also inhibited the generation of TER
(data not shown).
OCC2 Increases Paracellular Permeability
The decrease in TER caused by the OCC2 peptide could
be attributed to either an increase in paracellular tight
junction permeability or transcellular plasma membrane
permeability to ions. To distinguish between the two possi-
bilities, we assessed the flux of membrane-impermeant
paracellular tracer molecules across A6 cell monolayers.
Four different paracellular flux tracers were used: manni-
tol (mol wt 184), inulin (mol wt 5,200), dextran 3K (mol wt
3,000), and dextran 40K (mol wt 40,000). Newly formed
A6 monolayers (starting TER of z1,000 Vcm2) were
treated with 5 mM OCC1 or OCC2 for 36 h. At the end of
the 36 h of peptide treatment (when control TER devel-
oped to z2,500 Vcm2), paracellular tracer flux assays were
performed. As before, treatment of monolayers with
OCC2 resulted in a z10-fold reduction in TER from
z2,500 Vcm2 to z250 Vcm2. In the same monolayers,
OCC2 caused a z10-fold increase in the flux of paracel-
lular tracers (Fig. 3 a). The flux of mannitol (hydrody-
namic radius z4 Å), inulin (hydrodynamic radius z10–14
Å), and dextran 3K all increased z10-fold after OCC2
Figure 3. OCC2 increased the paracellular flux of membrane-
impermeant tracer molecules. (a) Effects of OCC2 on the flux of
[3H]mannitol, [14C]inulin, Texas red–conjugated neutral dextran
(mol wt 3,000), and Texas red–conjugated neutral dextran (mol
wt 40,000). OCC1 was used as control peptide. A6 cell monolay-
ers were allowed to grow until TER reached z1,200 Vcm2. Cell
monolayers were then treated with a final concentration of 5 ml
OCC1 or OCC2 for 36 h. TER was measured and tracers flux as-
says were performed as described in Materials and Methods. For
all four tracers, n 5 8 and error bars represent SEM. (b–e) The
relationship between tracer flux and TER changes induced by
OCC2 treatment. Absolute flux values for individual A6 cell
monolayers were plotted against TER of the same monolayer.
(b) [3H]mannitol, (c) [14C]inulin, (d) neutral dextran (mol wt
3,000) conjugated with Texas red, and (e) neutral dextran (mol wt
40,000) conjugated with Texas red.The Journal of Cell Biology, Volume 136, 1997 404
treatment. Therefore, the decrease in TER caused by
OCC2 peptide was associated with an increase in paracel-
lular permeability of the tight junction.
It was possible that OCC2 only altered the rates of
movement of these relatively small paracellular tracers
through the tight junction. To examine whether the func-
tional tight junction barrier to macromolecules was dis-
rupted by OCC2 peptide, the paracellular flux of dextran
40K, to which A6 cell monolayers are usually completely
impermeable, was measured. Indeed, treatment of A6 cell
monolayers with OCC2 opened the paracellular barrier to
dextran 40K (Fig. 3 a). OCC1 treatment had no detectable
effect on the flux of dextran 40K. Therefore, in addition to
reducing TER, the tight junction permeability barrier to
macromolecules of 40 kD was also compromised by OCC2
treatment.
For individual Transwell monolayers, there was a close
correlation between tracer fluxes and the magnitude of the
drop in TER. For this analysis, data from the experiments
shown in Fig. 3 a was replotted for individual Transwell
monolayers in Fig. 3, b–e. This correlation held for all four
tracers: mannitol (Fig. 3 b), inulin (Fig. 3 c), dextran 3,000
(Fig. 3 d), and dextran 40,000 (Fig. 3 e). This correlation
suggested that the decrease in TER caused by OCC2 was
predominantly, if not exclusively, due to the increase in
paracellular permeability. Therefore, we conclude that the
peptide corresponding to the second extracellular domain
of occludin perturbed the tight junction permeability bar-
rier function of the A6 cell monolayers.
OCC2 Selectively Decreases the Level of Occludin
in A6 Cells
To examine the potential effects of OCC2 on the tight
junction at the molecular level, the localization and total
cellular content of various known tight junction proteins
were determined. A6 cell monolayers that were used in
paracellular tracer flux assays (see above) were immedi-
ately processed for indirect immunofluorescence micros-
copy. OCC2-treated monolayers (TER z250 Vcm2) had
substantially less occludin present at cell boundaries as
compared with OCC1-treated monolayers (TER z2,500
Vcm2) (Fig. 4, a and b). On the other hand, ZO-1, ZO-2,
cingulin, and E-cadherin distributions were not changed
detectable by OCC2 treatment (Fig. 4, c–j). Therefore, it
appeared that OCC2 selectively depleted occludin from
the tight junction of A6 cells.
To confirm the depletion of occludin biochemically, we
performed Western blot analysis of various tight junction
proteins in A6 cell lysates that were treated for 24 h with
OCC1 (10 mM), OCC2 (10 mM), or DMSO solvent control
(0.1%). OCC2 selectively reduced total cellular occludin
levels but did not alter the levels of ZO-1, ZO-2, cingulin,
or E-cadherin (Fig. 5 a). Moreover, OCC1 had no effect
on the level of occludin. Total cellular occludin levels were
also unaltered by the scrambled peptide OCC2(S) and the
unmodified peptide OCC2(U) (Fig. 5 b). These results
suggested that the perturbation of the tight junction per-
meability barrier correlated with the selective reduction of
total cellular occludin levels but not the levels of other
junctional proteins, ZO-1, ZO-2, cingulin, and E-cadherin.
To determine whether the decreased occludin levels by
OCC2 treatment were due to an inhibition of occludin
Figure 4. OCC2 reduced junctional stainings of occludin but not
ZO-1, cingulin, ZO-2, and E-cadherin. A6 cell monolayers from
the paracellular tracer flux assays described in Fig. 3 were pro-
cessed for indirect immunofluorescence microscopy at the end of
the flux assays. OCC1-treated monolayers had TER of z2,500
Vcm2, and OCC2-treated monolayers had TER of z250 Vcm2.
OCC1-treated (a, c, e, g, and i) and OCC2-treated (b, d, f, h, and
j) monolayers were immunostained in parallel for occludin (a and
b), ZO-1 (c and d), cingulin (e and f), ZO-2 (g and h), and E-cad-
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protein synthesis or an enhancement of occludin turnover,
the effect of OCC2 on occludin synthesis and turnover was
tested. The synthesis of occludin was examined by briefly
metabolically labeling cellular proteins with [35S]methio-
nine (2.5-h pulse) followed by immunoprecipitation of oc-
cludin. Incorporation of [35S]methionine into occludin was
not altered by either 2 or 22 h of OCC2 treatment relative
to untreated cells. Therefore, it is unlikely that OCC2 de-
creased total cellular occludin levels by inhibiting occludin
synthesis (Fig. 5 c).
The effect of OCC2 on occludin turnover was deter-
mined by analyzing the disappearance of [35S]methionine-
labeled occludin from steady-state labeled cells (22 h). OCC2
peptide was added to the chase medium and, within 12 h
of chase, the amount of labeled occludin was noticeably
lower than that of untreated cells, suggesting that OCC2
caused occludin to turn over faster (Fig. 5 d). Therefore,
the depletion of cellular occludin by OCC2 was attributed
to an increase in occludin turnover.
TER Recovery after OCC2 Removal
If OCC2 decreased TER and occludin levels by specifi-
cally promoting occludin turnover rather than nonspecific
toxicity, A6 cells would be expected to remain healthy and
to be capable of reforming the tight junction permeability
barrier after the removal of OCC2. Therefore, we tested
the ability of A6 cell monolayers to recover TER after the
removal of OCC2 peptide. Newly formed monolayers
were treated with 5 mM OCC2 for 24 h, and TER dropped
from z2,000 Vcm2 to z180 Vcm2. OCC2-containing me-
dium was then removed from the cells and replaced with
fresh OCC2-free medium. After OCC2 removal, the TER
slowly increased and recovered to the initial pre-OCC2
treatment value in 48 h (Fig. 6 a). In fact, for the OCC2
peptide to maintain a continuous effect on TER, it is nec-
essary to replenish OCC2 every 48 h because cells that
were treated with only one dose of OCC2 recovered TER
readily. Immunofluorescence analysis of occludin showed
that the recovery of TER correlated with the reappear-
ance of occludin at the tight junction (Fig. 6 b). The revers-
ibility of the effect of OCC2 on both TER and occludin lo-
calization suggested that OCC2 only transiently altered the
ability of A6 cells to form tight junctions. Furthermore,
the correlation of TER recovery with occludin reappear-
ance at the tight junction again provided evidence for a
role of occludin in the formation of the tight junction per-
meability barrier.
Cell Morphology after OCC2 Treatment
The OCC2 peptide could act by disrupting the tight junc-
tion extensively, causing adjacent cells to separate from
each other. Alternatively, OCC2 might selectively perturb
the tight junction sealing element, leaving the overall tight
junction morphology relatively intact. Scanning EM was
used to examine the effect of OCC2 on A6 cell contacts.
Examination of gross cell morphology by scanning EM did
not reveal any detectable difference between cell mono-
layers that were treated for 30 h with DMSO (0.1%),
Figure 5. OCC2 specifically
decreased total cellular oc-
cludin levels. (a) Western
blots of occludin, cingulin,
ZO-1, ZO-2, and E-cadherin
of total cell lysates from
monolayers that were treated
with OCC1, OCC2, or
DMSO solvent control. A6
cells were allowed to grow
until TER reached z1,000
Vcm2, and monolayers were
treated with 10 mM of OCC1,
10  mM OCC2, or 0.1%
DMSO for 24 h. (b) Only the
peptide that decreased TER
also caused a decrease in oc-
cludin levels. Western blot of
occludin in A6 total cell ly-
sates of monolayers that
were treated with OCC1,
OCC2(U) (unmodified),
OCC2, or OCC2(S) (scram-
bled). A6 cells were allowed
to grow to confluency in nor-
mal medium and were subsequently changed to low calcium medium for 18 h. A6 cells were then replenished with normal calcium me-
dia containing peptides at a final concentration of 5 mM. OCC2(U), unmodified OCC2, and OCC2(S), scrambled sequence of OCC2.
Peptides were replenished every 24 h, and cells were extracted for analysis at 4 d after initial peptide treatment. (c) Occludin synthesis
was not reduced by OCC2 treatment. A6 cells that were either untreated or treated for either 2 or 22 h with a final concentration of 5
mM OCC2 were subsequently labeled for 2.5 h with [35S]methionine followed by immunoprecipitation (IP) of occludin. (d) Turnover of
occludin was enhanced by OCC2 treatment. A6 cells were metabolically labeled 20 h with [35S]methionine. At the end of the labeling
period (t 5 0), fresh media (without [35S]methionine) containing 10 mM OCC2 was added for 12 h followed by immunoprecipitation
(IP) of occludin. Untreated A6 cells were used in parallel as a control.The Journal of Cell Biology, Volume 136, 1997 406
OCC1 (10 mM), or OCC2 (10 mM) (Fig. 7). All monolay-
ers appeared intact and where characterized by a high
density of microvilli at cell boundaries. In addition, in pre-
liminary experiments, no changes in the tight junction, as
observed by transmission EM of thin-sections, were de-
tected (unpublished observations). However, a much
more extensive study would be necessary to determine the
effects of OCC2 at the ultrastructural level.
Discussion
A synthetic peptide (OCC2) corresponding to the entire
second extracellular domain of chick occludin was able to
consistently and significantly decrease TER when added
to Xenopus kidney epithelial A6 cell monolayers. The de-
crease in TER was attributed to a disruption of the tight
junction permeability barrier because it was associated with
an increase in paracellular flux of membrane-impermeant
tracers. The effect of OCC2 on the tight junction perme-
ability barrier correlated with a selective depletion of total
cellular levels and junctional localization of occludin. On
the other hand, the total cellular levels and localization of
cytoplasmic components of the tight (ZO-1, ZO-2, and
cingulin) and adherens (E-cadherens) junctions were not
affected. Furthermore, cell morphology, as observed by
scanning EM, was not altered. These results suggested that
the second extracellular domain peptide of occludin (OCC2)
acted specifically to perturb the permeability barrier func-
tion of the tight junction. The correlation of the physiolog-
ical effects of OCC2 with the selective reduction of occlu-
din provides evidence for a role for occludin in the
formation of a functional tight junction seal.
The effect of OCC2 did not appear to be caused by gen-
eral cell toxicity or perturbation of the plasma membrane.
First of all, the perturbation of epithelial permeability by
OCC2 occurred with only a maximal effective concentration
of 5 mM. Secondly, the slow time course of the effect of
OCC2, developing over 24 h of incubation, suggested that
the peptide did not act by perturbing plasma membrane
integrity, an effect that would be expected to be immedi-
ate. Thirdly, incubation of OCC2 for up to 5 d did not
cause changes in overall epithelial cell morphology, sug-
gesting that OCC2 was not detrimental to the cells. In fact,
if the observed increase in the flux of 40-kD dextran had
been caused by leaking through the plasma membrane, the
cells would not be expected to survive. Moreover, cells
that were treated with OCC2 excluded the vital dye, try-
pan blue, indicating that they remained intact and alive
(data not shown). Fourthly, the effect of OCC2 was re-
versible after removal of the peptide, indicating that
OCC2 did not impair the cells permanently but only tem-
porarily perturbed the tight junction permeability barrier.
In conclusion, OCC2 did not appear to be toxic to the cells
or disruptive to the integrity of the plasma membrane in a
nonspecific manner.
The effect of OCC2 appeared to be due to specific per-
turbation of the tight junction permeability barrier. First
of all, the effect was specific to the amino acid sequence of
OCC2 because only OCC2, but not OCC2(S), the scram-
bled sequence of the same amino acid composition as
OCC2, was able to decrease the TER of cell monolayers.
Secondly, the decrease in TER caused by OCC2 was asso-
Figure 6. The effects of OCC2 on TER and occludin accumula-
tion were reversible. (a) Reversibility of TER after OCC2 re-
moval. A6 cell monolayers that had TER of z1,700 Vcm2 were
treated at t 5 0 with a final concentration of 5 mM OCC1 or
OCC2. At t 5 24 h, peptides were either replenished (OCC1 and
OCC2) or removed (OCC2 Recovery) from the cells. OCC1 (n 5
6), OCC2 (n 5 6), and OCC2 recovery (n 5 3). (b) Recovery of
junctional stainings of occludin after OCC2 removal. A6 cell
monolayers that had TER z1,000 Vcm2 were treated at t 5 0
with a final concentration of 5 mM OCC1 or OCC2. At t 5 24 h,
peptides were either replenished (OCC1 and OCC2) or removed
(OCC2 recovery) from the cells. At t 5 60 h, cells were processed
for indirect immunofluorescence microscopy of occludin. OCC1
(TER z2,200 Vcm2), OCC2 (TER z250 Vcm2), and OCC2 re-
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ciated with an increase in the flux of membrane-imper-
meant tracers, demonstrating that OCC2 affected the
paracellular tight junction barrier. Thirdly, OCC2 did not
cause observable changes in epithelial cell morphology,
suggesting that the perturbation of the tight junction bar-
rier was not an indirect effect resulting from some gross
morphological alteration of the cells. Furthermore, OCC2
did not disrupt the entire epithelial junctional complex,
because neither the cellular levels nor the localization of
various known tight (ZO-1, ZO-2, and cingulin) and adhe-
rens (E-cadherin) junction proteins were altered. There-
fore, the physiological effects of OCC2 appeared to be due
to specific perturbation of the permeability seal of the
tight junction.
Although OCC2 caused cell monolayers to become per-
meable to macromolecular tracers, including dextran 40K,
the TERs of treated monolayers remained at significant
levels (z250 Vcm2). This suggests that the effect of OCC2
on cells within the monolayer was not homogeneous. It is
expected that regions of the monolayer responsible for
high tracer fluxes would also be areas of low electrical re-
sistance. Consistent with this explanation are the nonho-
mogeneous patterns of residual occludin staining after
OCC2 treatment (Fig. 4, a and b). Therefore, it is likely
that a fraction of the cells in the monolayers were partially
resistant to perturbation of the permeability barrier by
OCC2 treatment.
OCC2 had specific reproducible effects on occludin, the
protein from which it is derived. OCC2 selectively de-
pleted the cellular level and junctional localization of oc-
cludin without influencing the levels of other junctional
proteins examined. Control peptides that did not perturb
the tight junction permeability barrier, including a scram-
bled version of OCC2, OCC2(S), did not alter occludin
levels or localization. In addition, the amount of reduction
in occludin levels at various time points after OCC2 treat-
ment closely correlated with the magnitude of drop of TER
(data not shown). Moreover, after the removal of OCC2,
occludin expression and localization recovered completely
to normal levels. In fact, the time course of both the deple-
Figure 7. OCC2 did not cause morphological changes in A6 cell monolayers as observed by scanning EM. Confluent A6 cells grown on
polylysine-coated coverslips were treated 24 h with a final concentration of 10 mM OCC1 (a and d), 10 mM OCC2 (b and e), and 0.1%
DMSO (c and f). Cells were then processed for scanning EM. A6 cells were z7–10 mM in diam.The Journal of Cell Biology, Volume 136, 1997 408
tion and recovery of occludin correlated with the time
course of the physiological effects of OCC2. Thus, the se-
lective depletion of occludin from the tight junction ap-
peared to be a biochemical effect consistently associated
with the physiological action of the peptide. Therefore, we
propose that the depletion of occludin by OCC2 is the
mechanism by which OCC2 perturbed the tight junction
permeability barrier.
OCC2 behaves as if it is a competitive inhibitor of occlu-
din function that competes with endogenous occludin for
its receptor(s) or binding protein(s). Two possible mecha-
nisms of action of OCC2 could account for its perturbation
of the tight junction barrier. First, OCC2 could bind an oc-
cludin receptor by intercalating into the tight junction and
directly interfering with the normal function of a func-
tional seal. Secondly, OCC2, by binding to occludin recep-
tor(s), could cause the release of occludin from its normal
stabilized interactions in the tight junction, which subse-
quently leads to gradual disassembly of tight junction seal-
ing elements. Our results are consistent with the second
mechanism because the effect of OCC2 correlated with
the depletion of occludin, suggesting that disassembly of
sealing elements is the mechanism of OCC2 action.
Our results strongly implicate occludin in the formation
of the tight junction permeability barrier. Both the speci-
ficity of the OCC2 peptide sequence and the correlation of
occludin levels and TER support this contention. This con-
clusion is consistent with the findings that occludin is
present at the tight junction contact points and the in-
tramembrane fibrils (14, 15), the region defined as the oc-
cluding barrier where paracellular tracers do not permeate
through. The simplest model to explain how occludin might
participate in sealing the tight junction is that occludin po-
lymerizes in the plane of the plasma membrane and com-
pletely circumscribes the apex of cells. However, we do
not known whether occludin is the only component of the
fibrils or some other unidentified protein(s) also partici-
pate(s) in the formation of these fibrils. We also do not
know how occludin forms the cell–cell contact at the tight
junction. Does it bind to another occludin from the adja-
cent cell in a homophilic interaction or to an unidentified
protein in a heterophilic manner? Interestingly, prelimi-
nary data indicate that OCC2 peptide–coupled beads can
form a large aggregate, which might suggest that OCC2
binds to itself, perhaps reflecting either a homophilic bind-
ing event or polymerization of occludin (Wong, V., unpub-
lished data). Regardless of the mechanism, our findings
provide strong evidence for the functional role of occludin
in the tight junction permeability barrier.
The fact that occludin can be depleted from the tight
junction without affecting other known tight junction pro-
teins suggests that its incorporation into the tight junction
can be regulated separately. This can provide a potential
mechanism to regulate the permeability barrier function
of the tight junction without affecting the rest of the tight
junction structure. Instead of assembling and disassem-
bling the whole tight junction complex, the tight junction
permeability barrier could be regulated by recruiting and
removing occludin to and from the tight junction. This
could also help to explain the dynamic nature of the tight
junction, which must rapidly open and close during physio-
logical processes. Further experiments will be required to
determine whether the incorporation of occludin into the
tight junction is regulated physiologically.
The OCC2 peptide offers the possibility to selectively
and transiently eliminate the tight junction permeability
barrier without disrupting the general architecture of cells.
OCC2 treatment is the most specific means identified so
far to selectively perturb the paracellular barrier of the
tight junction. The transient perturbation of the barrier
function of the tight junction by OCC2 could be poten-
tially useful in medical therapeutics such as the facilitation
of drug delivery across the blood–brain barrier. The OCC2
sequence should be considered as just a starting point for
potential pharmaceutical development. It may be possible
to identify other occludin sequences or small molecules that
can optimally perturb occludin and the physiological prop-
erties of the tight junction.
We thank members of the Gumbiner laboratory for reading the manu-
script and for helpful discussions. We also thank Scott Geramanos for ex-
cellent technical work on the peptide chemistry.
This work was partially supported by Cancer Center Support grant
NCI-P30-CA-08748 and American Heart Association grant-in-aid 92006540.
V. Wong was partially supported by National Institutes of Health predoc-
toral grants, NRSA-DK07265-130031 and NRSA-DK07265-130031, and a
graduate opportunity fellowship from the University of California at San
Francisco.
Received for publication 30 July 1996 and in revised form 19 September 1996.
References
1. Anderson J.M., B.R. Stevenson, L.A. Jesaitis, D.A. Goodenough, and M.S.
Mooseker. 1988. Characterization of ZO-1, a protein component of the
tight junction from mouse liver and Madin-Darby canine kidney cells. J.
Cell Biol. 106:1141–1149.
2. Anderson, J.M., C.M. Van Itallie, M.D. Peterson, B.R. Stevenson, E.A.
Carew, and M.S. Mooseker. 1989. ZO-1 mRNA and protein expression
during tight junction assembly in Caco-2 cells. J. Cell Biol. 109:1047–1056.
3. Ando-Akatsuka, Y., M. Saitou, T. Hirase, M. Kishi, A. Sakakibara, M.
Itoh, S. Yonemura, M. Furuse, and S. Tsukita. 1996. Interspecies diver-
sity of the occludin sequence: cDNA cloning of human, mouse, dog, and
rat–kangaroo homologues. J. Cell Biol. 133:43–47.
4. Atisook, K., S. Carlson, and J.L. Madara. 1990. Effects of phlorizin and so-
dium on glucose-elicited alterations of cell junctions in intestinal epithe-
lia. Am. J. Physiol. 258:C77–C85.
5. Baker, J., and D. Garrod. 1993. Epithelial cells retain junctions during mi-
tosis. J. Cell Sci. 104:415–425.
6. Ballard, S.T., J.H. Hunter, and A.E. Taylor. 1995. Regulation of tight-junc-
tion permeability during nutrient absorption across the intestinal epithe-
lium. Annu. Rev. Nutr. 15:35–55.
7. Baron, D.A., and D.H. Miller. 1990. Extrusion of colonic epithelial cells in
vitro. J. Electron Microsc. Tech. 16:15–24.
8. Buse, P., P.L. Woo, D.B. Alexander, H.H. Cha, A. Reza, N.D. Sirota, and
G.L. Firestone. 1995. Transforming growth factor-a abrogates glucocorti-
coid-stimulated tight junction formation and growth suppression in rat
mammary epithelial tumor cells. J. Biol. Chem. 270:6505–6514.
9. Cereijido, M. 1992. Evolution of ideas on the tight junction. In Tight Junc-
tions. M. Cereijido, editor. CRC Press, Boca Raton, FL. 1–13.
10. Choi, Y.S., and B. Gumbiner. 1989. Expression of cell adhesion molecule
E-cadherin in Xenopus embryos begins at gastrulation and predominates
in the ectoderm. J. Cell Biol. 108:2449–2458.
11. Citi, S., H. Sabanay, R. Jakes, B. Geiger, and J. Kendrick-Jones. 1988. Cin-
gulin, a new peripheral component of tight junctions. Nature (Lond.).
333:272–276.
12. Citi, S., H. Sabanay, J. Kendrick-Jones, and B. Geiger. 1989. Cingulin: char-
acterization and localization. J. Cell Sci. 93:107–122.
13. Claude, P., and D.A. Goodenough. 1973. Fracture faces of zonulae occlu-
dentes from “tight” and “leaky” epithelia. J. Cell Biol. 58:390–400.
14. Fujimoto, K. 1995. Freeze-fracture replica electron microscopy combined
with SDS digestion for cytochemical labeling of integral membrane pro-
teins. J. Cell Sci. 108:3443–3449.
15. Furuse, M., T. Hirase, M. Itoh, A. Nagafuchi, S. Yonemura, S. Tsukita, and
S. Tsukita. 1993. Occludin: a novel integral membrane protein localizing
at tight junctions. J. Cell Biol. 123:1777–1788.
16. Furuse, M., M. Itoh, T. Hirase, A. Nagafuchi, S. Yonemura, S. Tsukita, and
S. Tsukita. 1994. Direct association of occludin with ZO-1 and its possible
involvement in the localization of occludin at tight junctions. J. Cell Biol.Wong and Gumbiner Occludin in Tight Junctions 409
127:1617–1626.
17. González-Mariscal, L., C. de Ramirez, and M. Cereijido. 1985. Tight junc-
tion formation in cultured epithelial cells (MDCK). J. Membr. Biol. 86:
113–125.
18. Gumbiner-B. 1987. Structure, biochemistry, and assembly of epithelial
tight junctions. Am. J. Physiol. 253:C749–C758.
19. Gumbiner, B., and K. Simons. 1986. A functional assay for proteins in-
volved in establishing an epithelial occluding barrier: identification of a
uvomorulin-like polypeptide. J. Cell Biol. 102:457–468.
20. Gumbiner, B., T. Lowenkopf, and D. Apatira. 1991. Identification of a 160
kD polypeptide that binds to the tight junction protein ZO-1. Proc. Natl.
Acad. Sci. USA. 88:3460–3464.
21. Hollander, D. 1988. Crohn’s disease—a permeability disorder of the tight
junction? Gut. 29:1621–1624.
22. Jesaitis, L.A., and D.A. Goodenough. 1994. Molecular characterization
and tissue distribution of ZO-2, a tight junction protein homologous to
ZO-1 and the Drosophila discs-large tumor suppressor protein. J. Cell Biol.
124:949–961.
23. Madara, J.L., and K. Dharmsathaphorn. 1985. Occluding junction struc-
ture-function relationships in a cultured epithelial monolayer. J. Cell
Biol. 101:2124–2133.
24. Madara, J.L., and J.S. Trier. 1980. Structural abnormalities of jejunal epi-
thelial cell membranes in Celiac Spruce. Lab. Invest. 43:254–261.
25. Meldolesi, J., G. Castiglioni, R. Parma, N. Nassivera, and P. de Camilli.
1978. Ca11-dependent disassembly and reassembly of occluding junc-
tions in guinea pig pancreatic acinar cells. J. Cell Biol. 79:156–172.
26. Milks, L.C., G.P. Conyers, and E.B. Cramer. 1986. The effect of neutrophil
migration on epithelial permeability. J. Cell Biol. 103:2729–2738.
27. Perkins, F.M., and J.S. Handler. 1981. Transport properties of toad kidney
epithelia in culture. Am. J. Physiol. 241:C154–C159.
28. Posalaky, Z., I. Posalaky, D. McGinley, and R.A. Meyer. 1989. The gastric
mucosal barrier: tight junction structure in gastritis and ulcer biopsies.
Virchows Archiv. A Pathol. Anat. 414:217–222.
29. Powell, D.W. 1981. Barrier function of epithelia. Am. J. Physiol. 241:G275–
G288.
30. Sagaties, M.J., G. Raviola, S. Schaeffer, and C. Miller. 1987. The structural
basis of the inner blood-retina barrier in the eye of Macaca mulatta. In-
vest. Ophthalmol. Visual. Sci. 28:2000–2014.
31. Schulzke, J.D., M. Fromm, M. Zeitz, H. Menge, E.O. Riecken, and C.J.
Bentzel. 1990. Tight junction regulation during impaired ion transport in
blood loops of rat jejunum. Res. Exp. Med. 190:59–68.
32. Stevenson, B.R., J.D. Siliciano, M.S. Mooseker, and D.A. Goodenough.
1986. Identification of ZO-1: a high molecular weight polypeptide associ-
ated with the tight junction (zonula occludens) in a variety of epithelia. J.
Cell Biol. 103:755–766.
33. Swift, J.G., T.M. Mukherjee, and R. Rowland. 1983. Intercellular junctions
in hepatocellular carcinoma. J. Submicrosc. Cytol. 15:799–810.
34. Wolburg, H., J. Neuhaus, U. Kniesel, B. Kraub, and E.-M. Schmid. 1994.
Modulation of tight junction structure in blood-brain barrier endothelial
cells. J. Cell Sci. 107:1347–1357.
35. Woo, L.P., H.H. Cha, K.L. Singer, and G.L. Firestone. 1996. Antagonistic
regulation of tight junction dynamics by glucocorticoids and transforming
growth factor-b in mouse mammary epithelial cells. J. Biol. Chem. 271:404–
412.
36. Zahraoui, A., G. Joberty, M. Arpin, J.J. Fontaine, R. Hellio, A. Tavitian,
and D. Louvard. 1994. A small rab GTPase is distributed in cytoplasmic
vesicles in nonpolarized cells but colocalizes with the tight junction
marker ZO-1 in polarized epithelial cells. J. Cell Biol. 124:101–115.
37. Zettl, K.S., M.D. Sjaastad, P.M. Riskin, G. Parry, T.E. Machen, and G.L.
Firestone. 1992. Glucocorticoid-induced formation of tight junctions in
mouse mammary epithelial cells in vitro. Proc. Natl. Acad. Sci. USA. 89:
9069–9073.
38. Zhong, Y., T. Saitoh, T. Minase, N. Sawada, K. Enomoto, and M. Mori.
1993. Monoclonal antibody 7H6 reacts with a novel tight junction–associ-
ated protein distinct from ZO-1, cingulin, and ZO-2. J. Cell Biol. 120:
477–483.
39. Zhong, Y., K. Enomoto, H. Isomura, N. Sawada, T. Minase, M. Oyamadaa,
Y. Konishi, and M. Mori. 1994. Localization of the 7H6 antigen at tight
junctions correlates with the paracellular barrier function of MDCK cells.
Exp. Cell Res. 214:614–620.